India Drug-Pricing Authority To Give Pharmas Incentives To Improve Products (India)
This article was originally published in PharmAsia News
India's National Pharmaceutical Pricing Authority plans a new system that would require drug makers to undergo more scrutiny on whether new ingredients and packaging materials improve the quality of their drug. The changes are intended to give pharmas incentives to make those changes because they then would be able to charge a higher price for their product if the changes improve quality. Drug makers have said the price controls placed on them in India kept the companies from making changes to extend the shelf life of their drugs and enhance their qualities. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.